Drug Overview

Alisertib is an advanced, investigational cancer medication that belongs to a class of “Smart Drugs” known as targeted therapy. Unlike traditional chemotherapy, which attacks all fast-growing cells, alisertib is designed to focus on a specific protein that helps cancer cells divide. This precision is intended to stop tumor growth while potentially reducing damage to healthy parts of the body.

Currently, alisertib is being used in clinical trials across the United States and Europe. It is being tested against several types of difficult-to-treat cancers, including lung cancer, breast cancer, and certain blood cancers.

Generic Name: Alisertib (also known as MLN8237)
US Brand Names: None (Currently an investigational drug)
Drug Class: Aurora A Kinase Inhibitor / Targeted Therapy
Route of Administration: Oral (Tablet)
FDA Approval Status: Not FDA Approved. It is currently in Phase II and Phase III clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To understand how alisertib works, we must look at how cells divide. Every time a cell splits into two, it uses a specific protein called Aurora A Kinase. This protein acts like a construction foreman, organizing the internal “scaffolding” (called microtubules) that pulls DNA apart so the cell can successfully divide.

In many types of cancer, the body produces way too much Aurora A Kinase. This causes cancer cells to divide much faster than normal cells.

Alisertib is a small molecule that enters the cancer cell and binds directly to the Aurora A Kinase protein. By “plugging up” this protein, alisertib prevents the scaffolding from forming correctly.

When the cancer cell tries to divide, the process becomes messy and broken. Because the cell cannot properly separate its DNA, it reaches a state called “mitotic arrest.” Eventually, the cell realizes it is too damaged to continue and triggers its own death (a process called apoptosis). By stopping the division at the source, alisertib helps shrink tumors and slow the spread of the disease.

FDA Approved Clinical Indications

Important Note: Because alisertib is an experimental medication, it does not currently have official FDA approval for general public use. However, it is being actively tested in clinical trials for the following investigational oncological uses:

Small Cell Lung Cancer (SCLC): Often studied in combination with other drugs for patients whose cancer has returned.
Breast Cancer: Specifically for advanced types that are hormone-receptor-positive.
T-cell Lymphoma: Including peripheral and cutaneous types.
Neuroblastoma: A rare type of cancer that often affects children.

Non-oncological uses:

None. This medication is strictly being studied for cancer treatment.

Dosage and Administration Protocols

Because alisertib is an investigational drug, the exact dose is decided by the specific rules of the clinical trial. Doctors are still finding the best dose that kills cancer with the fewest side effects.

Patient Type	Route	Standard Trial Dose Range	Frequency	Cycle Duration
Adults	Oral (Tablet)	30 mg to 50 mg	Twice Daily	7 days on, 14 days off
Pediatrics	Oral (Tablet)	Based on body surface area	Twice Daily	Varies by trial protocol

Dose Adjustments

Renal/Hepatic Insufficiency: Alisertib is processed by the liver. Patients with significant liver problems may need a lower dose or may be unable to join certain trials. Kidney function is also monitored, but liver health is the primary concern for this specific drug.

Clinical Efficacy and Research Results

Recent research from 2020 to 2025 has focused on using alisertib in combination with other therapies to make them work better.

Small Cell Lung Cancer: In Phase II trials, alisertib has shown the ability to extend “Progression-Free Survival” (the time a patient lives without the cancer getting worse). In some groups of patients with specific genetic markers (like MYC amplification), the drug worked significantly better than standard treatments.
Breast Cancer: Studies have shown that adding alisertib to hormone therapy can help overcome drug resistance, allowing the treatment to work for several months longer than hormone therapy alone.
Numerical Data: While survival rates vary, clinical trials have reported “Objective Response Rates” (tumor shrinkage) in approximately 20% to 25% of patients with certain aggressive lymphomas when using alisertib.

Safety Profile and Side Effects

Alisertib targets a protein involved in cell division, so it can affect other fast-growing healthy cells, such as those in the blood and the mouth.

Black Box Warning

There is no FDA Black Box Warning for alisertib because it is still in the testing phase.

Common Side Effects (>10%)

Neutropenia: A drop in white blood cell counts, which increases the risk of infection.
Anemia: Low red blood cell counts, leading to feeling very tired or weak.
Diarrhea: Frequent or loose bowel movements.
Nausea and Vomiting: Feeling sick to the stomach.
Mucositis: Painful sores or redness in the mouth and throat.

Serious Adverse Events

Febrile Neutropenia: A fever occurring when white blood cell counts are very low (this is a medical emergency).
Severe Dehydration: Caused by unmanaged diarrhea or vomiting.

Management Strategies

For Low Blood Counts: Doctors will perform regular blood tests. They may prescribe “growth factor” shots to help your body make more white blood cells.
For Mouth Sores: Use a soft toothbrush and avoid spicy or acidic foods. Your doctor may suggest a special “magic mouthwash” to numb the pain.
For Diarrhea: Drink plenty of fluids with electrolytes and use over-the-counter anti-diarrheal medicine if approved by your trial team.

Research Areas

Alisertib is a major focus in Combination Immunotherapy research. Scientists are currently exploring how alisertib can be used alongside “checkpoint inhibitors” (a type of immunotherapy). The idea is that alisertib breaks down the cancer cells, making them “visible” to the immune system. This could regenerate a stronger immune response, allowing the body to fight the cancer more effectively.

Patient Management and Practical Recommendations

Pre-Treatment Tests

Complete Blood Count (CBC): To check your starting levels of white cells, red cells, and platelets.
Liver Function Tests: To ensure your liver can process the medication.
Pregnancy Test: Alisertib can harm an unborn baby.

Precautions during treatment

Avoid Infection: Wash your hands often and stay away from people who are sick, especially when your white blood cell counts are low.

“Do’s and Don’ts”

DO take the tablets at the same time every day with a full glass of water.
DO tell your doctor immediately if you develop a fever or a sore throat.
DON’T crush, chew, or break the tablets.
DON’T eat grapefruit or drink grapefruit juice, as it can change how much medicine is in your blood.

Legal Disclaimer

The information provided in this guide is for educational purposes only and does not constitute medical advice. It should not be used to diagnose or treat any health condition. Always consult with a qualified healthcare professional or your oncologist regarding treatment options or before starting any medication. Every patient’s situation is unique, and therapies must be managed by a licensed physician.